Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 239 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Primary Progressive Aphasia (PPA) Clear all
Active, not recruiting No phase listed Observational Accepts healthy volunteers

TRIAL READY (Clinical Trial Readiness)

NCT03912987
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, ALS-Frontotemporal Dementia, Primary Lateral Sclerosis, Progressive Muscular Atrophy
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
610 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2031
U.S. locations
3
States / cities
Miami, Florida • Kansas City, Kansas • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 5, 2026, 5:44 PM EDT
Not listed Phase 1Phase 2 Interventional

Transcranial Electromagnetic Treatment (TEMT) Against Alzheimer's Disease

NCT04271163
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MemorEM
Device
Lead sponsor
NeuroEM Therapeutics, Inc.
Industry
Eligibility
63 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 5, 2026, 5:44 PM EDT
Recruiting Not applicable Interventional

Enhancing Language Function in Primary Progressive Aphasia

NCT04920318
View directory record Official record
Conditions
Primary Progressive Aphasia
Interventions
tDCS + language therapy, sham TDCS + language therapy
Combination Product
Lead sponsor
University of Arizona
Other
Eligibility
45 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 5, 2026, 5:44 PM EDT
Completed Phase 1 Interventional

Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)

NCT02939547
View directory record Official record
Conditions
Niemann-Pick Disease, Type C1
Interventions
Hydroxypropyl-beta-cyclodextrin
Drug
Lead sponsor
Cyclo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Oakland, California • Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 5, 2026, 5:44 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Study of Social Behavior and Emotion in Frontotemporal Dementia, Alzheimer's Disease and Controls

NCT01147679
View directory record Official record
Conditions
Frontotemporal Dementia, Frontotemporal Degeneration, Alzheimer's Disease, Social Behavior
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2011 · Synced Oct 5, 2026, 5:44 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

NCT07498426
View directory record Official record
Conditions
Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Interventions
NIO752, Placebo
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
41 Years to 81 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Scottsdale, Arizona • San Francisco, California • Englewood, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 5, 2026, 5:44 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Living With Frontotemporal Dementia

NCT01738386
View directory record Official record
Conditions
Adaptation
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 5, 2026, 5:44 PM EDT
Recruiting Not applicable Interventional

Using the EHR to Advance Genomic Medicine Across a Diverse Health System

NCT06377033
View directory record Official record
Conditions
Genetic Predisposition, Paraganglioma, Pheochromocytoma, ALS, Parkinson Disease, Polyneuropathies, Frontotemporal Dementia, Alzheimer Disease, Cardiomyopathy Non-ischemic, Thoracic Aortic Aneurysm
Interventions
Behavioral nudge
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 5, 2026, 5:44 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Phenotype, Genotype and Biomarkers 2

NCT04875416
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Hereditary Spastic Paraplegia, Primary Lateral Sclerosis, Progressive Muscular Atrophy, Frontotemporal Dementia
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
7 Years and older
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
3
States / cities
Miami, Florida • Kansas City, Kansas • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 5, 2026, 5:44 PM EDT
Completed No phase listed Observational

Feasibility of Passive Data Collection in Dementia Subjects With Agitation

NCT04413851
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Vascular Dementia, Frontotemporal Dementia, Lewy Body Dementia, Mixed Dementia
Interventions
Not listed
Lead sponsor
HealthMode Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Tucson, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 5, 2026, 5:44 PM EDT
Recruiting No phase listed Observational

The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech

NCT03313011
View directory record Official record
Conditions
Apraxia of Speech, Non-fluent Aphasia, Primary Progressive Aphasia, Primary Progressive Nonfluent Aphasia
Interventions
Testing protocol for the study
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 5, 2026, 5:44 PM EDT
Completed Not applicable Interventional

A Prospective and Retrospective Cohort Study in Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD)

NCT04106544
View directory record Official record
Conditions
Sphingomyelin Lipidosis
Interventions
Investigational Procedures
Procedure
Lead sponsor
Sanofi
Industry
Eligibility
Not listed
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Atlanta, Georgia • The Bronx, New York • Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Oct 5, 2026, 5:44 PM EDT
Completed Not applicable Interventional

Communication Bridge Speech Therapy Research Study

NCT02439853
View directory record Official record
Conditions
Primary Progressive Aphasia, Frontotemporal Dementia
Interventions
Monthly Check-in Session
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
Not listed
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 5, 2026, 5:44 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency

NCT01371825
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency, Wolman Disease
Interventions
Sebelipase alfa (SBC-102)
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 24 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 5, 2026, 5:44 PM EDT
Completed Phase 4 Interventional Results available

Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia

NCT00545974
View directory record Official record
Conditions
Frontal Lobe Dementia, Frontotemporal Lobe Dementia, Semantic Dementia
Interventions
memantine, Placebo pill
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 80 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 5, 2026, 5:44 PM EDT
Enrolling by invitation Phase 2 Interventional

The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31

NCT07264283
View directory record Official record
Conditions
PSP - Progressive Supranuclear Palsy
Interventions
LM11A-31, Matching Placebo
Drug
Lead sponsor
Adam Boxer
Other
Eligibility
41 Years to 86 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 5, 2026, 5:44 PM EDT
Recruiting No phase listed Observational

Language in Primary Progressive Aphasia

NCT00537004
View directory record Official record
Conditions
Primary Progressive Aphasia
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 5, 2026, 5:44 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

BioFINDER-Brown: Examination of Alzheimer's Disease Biomarkers

NCT05457998
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia
Interventions
Flutemetamol F18 Injection, [18F]-RO6958948 Injection, [18F]-MK-6240 Injection
Diagnostic Test
Lead sponsor
Butler Hospital
Other
Eligibility
50 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 5, 2026, 5:44 PM EDT
Recruiting Phase 2 Interventional

Communication Bridge 3 Study

NCT06191198
View directory record Official record
Conditions
Primary Progressive Aphasia
Interventions
Communication Bridge™, Evidence-Based Impairment Focused
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 5, 2026, 5:44 PM EDT
Terminated Phase 2 Interventional Results available

Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism

NCT00668564
View directory record Official record
Conditions
Hurler's Syndrome, Maroteaux-Lamy Syndrome, Sly Syndrome, Alpha Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Sphingolipidoses, Krabbe Disease, Wolman's Disease, Niemann-Pick Disease Type B, Niemann-Pick Disease, Type C
Interventions
Stem Cell Transplantation, Cyclophosphamide, Campath-1H, Busulfan
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 21 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 5, 2026, 5:44 PM EDT
Enrolling by invitation No phase listed Observational

Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders

NCT04680130
View directory record Official record
Conditions
PSP, CBD, PCA, LPA, Semantic Dementia, Semantic Aphasia, Behavioral Variant of Frontotemporal Dementia, FTD, PPA, Apraxia of Speech, MSA - Multiple System Atrophy, Parkinson Disease
Interventions
C-11 PiB, AV1451 Tau, C-11 ER176
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2050
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 5, 2026, 5:44 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

The Healthy Patterns Sleep Study

NCT03682185
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Circadian Rhythm Disorders, Circadian Rhythm Sleep Disorder, Insomnia, Hypersomnia, Cognitive Impairment, Cognitive Decline, Mild Cognitive Impairment, Frontotemporal Dementia, Neurocognitive Disorders, Vascular Dementia, Sleep Disorder, Memory Impairment
Interventions
Attention-Control Condition, Timed Activity Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 110 Years
Enrollment
421 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 5, 2026, 5:44 PM EDT
Not listed Phase 1 Interventional

Open-Label Study of Long-Term Safety and Efficacy of Intravenous Trappsol Cyclo (HPβCD) in Niemann-Pick Disease Type C

NCT03893071
View directory record Official record
Conditions
Niemann-Pick Disease, Type C1
Interventions
Hydroxypropyl-β-cyclodextrin
Drug
Lead sponsor
Cyclo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 5, 2026, 5:44 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial

NCT05189106
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Baricitinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 5, 2026, 5:44 PM EDT